Details

Autor(en) / Beteiligte

• Di Marco, Andrea
• Anguera, Ignasi
• Nombela‐Franco, Luis
• Oloriz, Teresa
• Teruel, Luis
• Rodriguez Mañero, Moisés
• Toquero, Jorge
• León, Valentina
• Dallaglio, Paolo
• Perez Guerrero, Ainhoa
• Salazar, Carlos Hernando
• Escaned, Javier
• Asso Abadía, Antonio
• Gomez Hospital, Joan Antoni
• Cequier, Angel

Titel

Revascularization of coronary chronic total occlusions in an infarct‐related artery and recurrence of ventricular arrhythmias among patients with secondary prevention implantable cardioverter defibrillator

Ist Teil von

• Catheterization and cardiovascular interventions, 2021-01, Vol.97 (1), p.E1-E11

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2021

Quelle

Wiley Online Library

Beschreibungen/Notizen

• Objectives To evaluate whether the revascularization of a coronary chronic total occlusion in an infarct‐related artery (IRACTO) may be associated with lower recurrence of ventricular arrhythmias (VA) among patients with a secondary prevention implantable cardioverter defibrillator (ICD). Background IRACTO is increasingly recognized as an independent predictor of VA. It is unknown whether IRACTO revascularization can reduce the burden of VA. Methods Multicenter observational cohort study that included consecutive patients with prior myocardial infarction and secondary prevention ICD. The primary endpoint was any appropriate ICD therapy. Results Among the 460 patients included, 269 (58%) had at least one IRACTO at the coronary angiogram performed before ICD implantation; of these, 20 (7%) had their IRACTO successfully revascularized (IRACTO‐R) afterwards. During a median follow‐up of 48 months, 229 patients (49%) had at least one appropriate ICD therapy. Patients with IRACTO not revascularized (IRACTO‐NR) had the highest incidence of ICD therapies (65%) while patients with IRACTO‐R had the lowest (10%, p < .001). In the entire cohort, IRACTO‐NR was an independent predictor of appropriate ICD therapies (HR 2.85, p < .001) and appropriate ICD shocks (HR 2.94, p < .001). Among patients with IRACTO at baseline, IRACTO‐R was independently associated with a marked reduction of appropriate ICD therapies (HR 0.12, p = .002) and appropriate ICD shocks (HR 0.21, p = .03). Conclusions In patients with prior myocardial infarction and secondary prevention ICD, IRACTO revascularization was independently associated with a markedly lower incidence of appropriate ICD therapies and shocks. These results should be corroborated by larger prospective studies.